Tags

Type your tag names separated by a space and hit enter

Proteomics: from hypothesis to quantitative assay on a single platform. Guidelines for developing MRM assays using ion trap mass spectrometers.
Brief Funct Genomic Proteomic. 2008 Sep; 7(5):340-54.BF

Abstract

High-throughput HPLC-mass spectrometry (HPLC-MS) is routinely used to profile biological samples for potential protein markers of disease, drug efficacy and toxicity. The discovery technology has advanced to the point where translating hypotheses from proteomic profiling studies into clinical use is the bottleneck to realizing the full potential of these approaches. The first step in this translation is the development and analytical validation of a higher throughput assay with improved sensitivity and selectivity relative to typical profiling assays. Multiple reaction monitoring (MRM) assays are an attractive approach for this stage of biomarker development given their improved sensitivity and specificity, the speed at which the assays can be developed and the quantitative nature of the assay. While the profiling assays are performed with ion trap mass spectrometers, MRM assays are traditionally developed in quadrupole-based mass spectrometers. Development of MRM assays from the same instrument used in the profiling analysis enables a seamless and rapid transition from hypothesis generation to validation. This report provides guidelines for rapidly developing an MRM assay using the same mass spectrometry platform used for profiling experiments (typically ion traps) and reviews methodological and analytical validation considerations. The analytical validation guidelines presented are drawn from existing practices on immunological assays and are applicable to any mass spectrometry platform technology.

Authors+Show Affiliations

Lilly Corporate Center, Drop Code GL54, Indianapolis, IN 46285, USA. bomiehan@lilly.comNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18579614

Citation

Han, Bomie, and Richard E. Higgs. "Proteomics: From Hypothesis to Quantitative Assay On a Single Platform. Guidelines for Developing MRM Assays Using Ion Trap Mass Spectrometers." Briefings in Functional Genomics & Proteomics, vol. 7, no. 5, 2008, pp. 340-54.
Han B, Higgs RE. Proteomics: from hypothesis to quantitative assay on a single platform. Guidelines for developing MRM assays using ion trap mass spectrometers. Brief Funct Genomic Proteomic. 2008;7(5):340-54.
Han, B., & Higgs, R. E. (2008). Proteomics: from hypothesis to quantitative assay on a single platform. Guidelines for developing MRM assays using ion trap mass spectrometers. Briefings in Functional Genomics & Proteomics, 7(5), 340-54. https://doi.org/10.1093/bfgp/eln032
Han B, Higgs RE. Proteomics: From Hypothesis to Quantitative Assay On a Single Platform. Guidelines for Developing MRM Assays Using Ion Trap Mass Spectrometers. Brief Funct Genomic Proteomic. 2008;7(5):340-54. PubMed PMID: 18579614.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Proteomics: from hypothesis to quantitative assay on a single platform. Guidelines for developing MRM assays using ion trap mass spectrometers. AU - Han,Bomie, AU - Higgs,Richard E, Y1 - 2008/06/25/ PY - 2008/6/27/pubmed PY - 2009/2/13/medline PY - 2008/6/27/entrez SP - 340 EP - 54 JF - Briefings in functional genomics & proteomics JO - Brief Funct Genomic Proteomic VL - 7 IS - 5 N2 - High-throughput HPLC-mass spectrometry (HPLC-MS) is routinely used to profile biological samples for potential protein markers of disease, drug efficacy and toxicity. The discovery technology has advanced to the point where translating hypotheses from proteomic profiling studies into clinical use is the bottleneck to realizing the full potential of these approaches. The first step in this translation is the development and analytical validation of a higher throughput assay with improved sensitivity and selectivity relative to typical profiling assays. Multiple reaction monitoring (MRM) assays are an attractive approach for this stage of biomarker development given their improved sensitivity and specificity, the speed at which the assays can be developed and the quantitative nature of the assay. While the profiling assays are performed with ion trap mass spectrometers, MRM assays are traditionally developed in quadrupole-based mass spectrometers. Development of MRM assays from the same instrument used in the profiling analysis enables a seamless and rapid transition from hypothesis generation to validation. This report provides guidelines for rapidly developing an MRM assay using the same mass spectrometry platform used for profiling experiments (typically ion traps) and reviews methodological and analytical validation considerations. The analytical validation guidelines presented are drawn from existing practices on immunological assays and are applicable to any mass spectrometry platform technology. SN - 1477-4062 UR - https://www.unboundmedicine.com/medline/citation/18579614/Proteomics:_from_hypothesis_to_quantitative_assay_on_a_single_platform__Guidelines_for_developing_MRM_assays_using_ion_trap_mass_spectrometers_ L2 - https://www.lens.org/lens/search/patent/list?q=citation_id:18579614 DB - PRIME DP - Unbound Medicine ER -